Analysis Of Income And Expense [Abstract]

PCI Biotech Holding - Filing #5867918

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Analysis of income and expense [abstract]
Material income and expense [abstract]
Research and development expense
16 062 NOK
15 627 NOK
Finance income (cost)
1 538 NOK
1 926 NOK
Selling, general and administrative expense [abstract]
General and administrative expense
8 628 NOK
9 604 NOK
Operating expense
24 690 NOK
25 231 NOK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
16 417 NOK
- NOK
16 417 NOK
- NOK
- NOK
20 315 NOK
20 315 NOK
- NOK
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
16 417 NOK
20 315 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.